Chemokines and MS lesion development

International MS Journal

Volumn 9, Issue 3, 2002, Pages 100-107

  Kallmann, Boris A ^a   Rieckmann, Peter ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CHEMOKINE; ANGIOGENIC FACTOR; ARGININE; BETA CHEMOKINE; CHEMOATTRACTANT; CHEMOKINE; CHEMOKINE RECEPTOR; CYSTEINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUTAMIC ACID; INTERLEUKIN 8; LEUCINE; MACROPHAGE INFLAMMATORY PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 2; MELANOMA GROWTH STIMULATORY ACTIVITY FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOKINE; RANTES;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; CELLULAR IMMUNITY; CHROMOSOME 4; ENDOTHELIUM CELL; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; INFLAMMATION; INFLAMMATORY CELL; INFLAMMATORY INFILTRATE; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PATHOPHYSIOLOGY; PROTEIN FUNCTION; PROTEIN MOTIF; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 0036446931     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
2. Mackay CR. Chemokines: Immunology's high impact factors. Nat Immunol 2001; 2: 95-101.
3. Zlotnik A, Yoshie O. Chemokines: A new classification system and their role in immunity. Immunity 2000; 12: 121-127.
4. Strieter RM, Polverini PJ, Kunkel SL, Arenberg DA, Burdick MD, Kasper J et al. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J Biol Chem 1995; 270: 27348-27357.
5. Ransohoff RM. Chemokines in neurological disease models: Correlation between chemokine expression patterns and inflammatory pathology. J Leukoc Biol 1997; 62: 645-652.
6. Godiska R, Chantry D, Dietsch GN, Gray PW. Chemokine expression in murine experimental allergic encephalomyelitis. J Neuroimmunol 1995; 58: 167-176.
7. Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Miller SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol 1995; 155: 5003-5010.
8. Glabinski AR, Tani M, Strieter RM, Tuohy VK, Ransohoff RM. Synchronous synthesis of alpha- and beta-chemokines by cells of diverse lineage in the central nervous system of mice with relapses of chronic experimental autoimmune encephalomyelitis. Am J Pathol 1997; 150: 617-630.
9. Jiang Y, Salafranca MN, Adhikari S, Xia Y, Feng L, Sonntag MK et al. Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmmunol 1998; 86: 1-12.
10. Owens T, Wekerle H. Antel J. Genetic models for CNS inflammation. Nat Med 2001; 7: 161-166.
11. Glabinski AR, Krakowski M, Han Y, Owens T, Ransohoff RM. Chemokine expression in GKO mice (lacking interferon-gamma) with experimental autoimmune encephalomyelitis. J Neurovirol 1999; 5: 95-101.
12. Fuentes ME, Durham SK, Swerdel MR, Lewin AC, Barton DS, Megill JR et al. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 1995; 155: 5769-5776.
13. Fife BT, Huffnagle GB, Kuziel WA, Karpus NJ. CC chemokine receptor 2 is critical for induction of experimental autoimmune encephalomyelitis. J Exp Med 2000; 192: 899-905.
14. Tran EH, Kuziel WA, Owens T. Induction of experimental autoimmune encephalomyelitis in C57BL/6 mice deficient in either the chemokine macrophage inflammatory protein-1alpha or its CCR5 receptor. Eur J Immunol 2000; 30: 1410-1415.
15. Miyagishi R, Kikuchi S, Fukazawa T, Tashiro K. Macrophage inflammatory protein-1 alpha in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological diseases. J Neurol Sci 1995; 129: 223-227.
16. Sorensen TL, Tani M, Jensen J, Pierce V, Lucchinetti C, Folcik VA et al. Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. J Clin Invest 1999; 103: 807-815.
17. Lahrtz F, Piali L, Spanaus KS, Seebach J, Fontana A. Chemokines and chemotaxis of leukocytes in infectious meningitis. J Neuroimmunol 1998; 85: 33-43.
18. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of monocyte chemoattractant protein-1-and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J Neuroimmunol 1998; 84: 238-249.
19. McManus C, Berman JW, Brett FM, Staunton H, Farrell M, Brosnan CF. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: An immunohistochemical and in situ hybridization study. J Neuroimmunol 1998; 86: 20-29.
20. Balashov KE, Rottman JB, Weiner HL, Hancock WW. CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. Proc Natl Acad Sci U S A 1999; 96: 6873-6878.
21. Iarlori C, Reale M, Lugaresi A, De Luca G, Bonanni L, Di Iorio A et al. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b. J Neuroimmunol 2000; 107: 100-107.
22. Bennetts BH, Teutsch SM, Buhler MM, Heard RN, Stewart GJ. The CCR5 deletion mutation fails to protect against multiple sclerosis. Hum Immunol 1997; 58: 52-59.
23. Barcellos LF, Schito AM, Rimmler JB, Vittinghof E, Shih A, Lincoln R et al. CC-chemokine receptor 5 polymorphism and age of onset in familial multiple sclerosis. Multiple Sclerosis Genetics Group. Immunogenetics 2000; 51: 281-288.
24. Kallmann BA, Hummel V, Klein O, Rieckmann P. Differential gene expression in human cerebral endothelial cells. Endothelium 2001; 8: 308.
25. Kallmann BA, Wagner S, Hummel V, Buttmann M, Bayas A, Tonn JC et al. Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J 2002; 16: 589-591.
26. Van Der Voorn P, Tekstra J, Beelen RH, Tensen CP, Van Der Valk P, De Groot CJ. Expression of MCP-1 by reactive astrocytes in demyelinating multiple sclerosis lesions. Am J Pathol 1999; 154: 45-51.
27. Simpson JE, Newcombe J, Cuzner ML, Woodroofe MN. Expression of the interferon-gamma-inducible chemokines IP-10 and Mig and their receptor, CXCR3, in multiple sclerosis lesions. Neuropathol Appl Neurobiol 2000; 26: 133-142.
28. Barnes DA, Huston M, Holmes R, Benveniste EN, Yong VW, Scholz P et al. Induction of RANTES expression by astrocytes and astrocytoma cell lines. J Neuroimmunol 1996; 71: 207-214.
29. Hvas J, McLean C, Justesen J, Kannourakis G, Steinman L, Oksenberg JR et al. Perivascular T cells express the pro-inflammatory chemokine RANTES mRNA in multiple sclerosis lesions. Scand J Immunol 1997; 46: 195-203.
30. Zang YC, Samanta AK, Halder JB, Hong J, Tejada-Simon MV, Rivera VM et al. Aberrant T cell migration toward RANTES and MIP-1 alpha in patients with multiple sclerosis. Overexpression of chemokine receptor CCR5. Brain 2000; 123: 1874-1882.
31. Biddison WE, Cruikshank WW, Center DM, Pelfrey CM, Taub DD, Turner RV. CD8+ myelin peptide-specific T cells can chemoattract CD4+ myelin peptide-specific T cells: Importance of IFN- inducible protein 10. J Immunol 1998; 160: 444-448.
32. Campbell JJ, Butcher EC. Chemokines in tissue-specific and microenvironment-specific lymphocyte homing. Curr Opin Immunol 2000; 12: 336-341.
33. Cross AK, Woodroofe MN. Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. Glia 1999; 28: 183-189.
34. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-107.
35. Karpus WJ, Kennedy KJ. MIP-1alpha and MCP-1 differentially regulate acute and relapsing autoimmune encephalomyelitis as well as Th1/Th2 lymphocyte differentiation. J Leukoc Biol 1997; 62: 681-687.
36. Wojcik WJ, Swoveland P, Zhang X, Vanguri P. Chronic intrathecal infusion of phosphorothioate or phosphodiester antisense oligonucleotides against cytokine responsive gene-2/IP-10 in experimental allergic encephalomyelitis of lewis rat. J Pharmacol Exp Ther 1996; 278: 404-410.
37. Youssef S, Wildbaum G, Maor G, Lanir N, Gour-Lavie A, Grabie N et al. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C-C chemokines. J Immunol 1998; 161: 3870-3879.
38. Karpus WJ, Lukacs NW. The role of chemokines in oral tolerance. Abrogation of nonresponsiveness by treatment with antimonocyte chemotactic protein-1. Ann N Y Acad Sci 1996; 778: 133-144.
39. Zang YC, Halder JB, Samanta AK, Hong J, Rivera VM, Zhang JZ. Regulation of chemokine receptor CCR5 and production of RANTES and MIP-1alpha by interferon-beta. J Neuroimmunol 2001; 112: 174-180.
40. Li QQ, Bever CT. Glatiramer acetate blocks interleukin-1-dependent nuclear factor-kappaB activation and RANTES expression in human U-251 MG astroglial cells. Brain Res Mol Brain Res 2001; 87: 48-60.
41. Liang M, Mallari C, Rosser M, Ng HP, May K, Monahan S et al. Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1. J Biol Chem 2000; 275: 19000-19008.